Multiple Sclerosis, Disease-Modifying Therapies, and Infections.

Neurol Neuroimmunol Neuroinflamm · 2023 · PMC10574822 · PMID 37813594

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Treatment with rituximab, fingolimod, and to a lesser extent, natalizumab were associated with similarly increased aRR of all outpatient infections compared with general population controls and IFN/GLAT-treated patients, although the aRR of outpatient infections for natalizumab compared with IFN/GLAT did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.